University of California, Los Angeles
Los Angeles, United States
Dr. Cloughesy is a professor of neurology at the David Geffen School of Medicine at the University of California, Los Angeles and a member of the UCLA Brain Research Institute and Jonsson Comprehensive Cancer Center. He also serves as the director of UCLA’s Neuro-Oncology Program, co-director of the UCLA Brain Tumor Center, and the director of the Henry Singleton Brain Cancer Research Program.
Dr. Cloughesy’s research includes therapeutic, imaging, translational and basic investigations. His experience with clinical trials includes therapeutic approaches such as small molecule inhibitors, antibodies, antibody drug conjugates, chemotherapies, vaccines, viral gene transfer, and immune check point therapies. He has experience in leadership roles for first in human, PK/PD, and more traditional Phase I through Phase III studies. His focus on clinical trials in brain cancer involves novel clinical trial design, incorporation of biomarkers and development of new biomarkers. He provided principal leadership for the accelerated approval and the conversion to full approval of the drug bevacizumab for recurrent glioblastoma. He has developed a brain cancer bioinformatics database which combines clinical outcomes, imaging, and molecular analysis to foster and enhance translational research. He has authored or co-authored over 420 peer-reviewed articles on brain cancer and has a Google Scholar H index > 124. He receives funding from NIH, NBTS, IVY Foundation and other private foundations, including a recent Brain Cancer SPORE at UCLA where he functions as co-principal investigator. He is the principal investigator for GBM AGILE which was created as a master protocol utilizing an adaptive Bayesian approach for late stage glioblastoma development.